
News|Articles|February 13, 2019
Yupelri for Chronic Obstructive Pulmonary Disease
Author(s)Drew Boxler
Advertisement
Yupelri (revefenacin, Mylan®)
Indications: Patients with chronic obstructive pulmonary disease
Dosage: One 175 mcg vial (3 mL) once daily.
Contraindications: hypersensitivity to revefenacin or any component of this product.
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Orforglipron Maintains Weight Loss After Discontinuation of Injectable GLP-1
2
FDA Approves Tradipitant for Prevention of Vomiting From Motion Sickness
3
Rethinking Acute Pain Management in the Age of Prescription Topicals
4
Pharmacists Must Effectively Balance Risks, Benefits of Social Media Use
5














































































































